Stanford University
Showing 61-80 of 228 Results
-
Joshua Gillard
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Josh Gillard is a Canadian biomedical data scientist with experience in bioinformatics, machine learning, and immunology. After completing a BSc and a MSc in Experimental Medicine at McGill university, he relocated to the Netherlands for his PhD in bioinformatics at Radboud University in Nijmegen. During his PhD, he gained experience analyzing and interpreting complex immunological data (bulk and single-cell transcriptomics, high-dimensional cytometry, high-throughput proteomics) derived from human observational or intervention studies (vaccination and experimental human infection) in order to discover molecular and cellular correlates of clinically important endpoints such as disease severity, symptom progression, and antibody responses. In 2022, Josh relocated to Stanford to join the Gaudilliere lab to develop and apply multi-omic data integration and machine learning techniques, establishing that early gestational immune dysregulation can predict preterm birth. Since 2024, in the Ashley lab, Josh is focused on applying deep learning models to investigate aberrant splicing in cardiovascular disease.
-
Diona Gjermeni
Affiliate, Med/Stanford Center for Clinical Research
Visiting Scholar, Medicine - Med/Cardiovascular MedicineBioDiona Gjermeni is a board-certified physician specialized in both Internal Medicine and Cardiology (Germany). With a strong focus on clinical research, her previous work primarily revolves around antithrombotic therapy and personalized medicine.
Currently affiliated with Stanford University, as a research fellow she is actively engaged in the Stanford Center for Clinical Research (SCCR), where he is gaining expertise in the conduct of clinical trials within the field of cardiovascular medicine. She is currently involved in a variety of clinical trials spanning multiple phases, with a particular emphasis on digital health, heart failure, and arrhythmias. Her research aims to improve patient outcomes through innovative therapies and precision medicine. Looking ahead, Dr. Gjermeni's long-term professional goal is to specialize in Electrophysiology, where she hopes to contribute further to the advancement of cardiovascular care. -
Bruna Gomes
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly InterestsThe increasing availability of very large datasets, along with recent advances in deep learning based tools for automatic extraction of cardiac traits, has led to the discovery of further common variants associated with cardiac disease. However, the genetic underpinnings of valvular heart disease remains understudied. I am interested in developing deep learning techniques to automatically extract cardiac flow information to facilitate genome-wide association studies of cardiac flow traits.
-
Francois Haddad
Clinical Professor, Medicine - Cardiovascular Medicine
BioDr. Francois Haddad, MD is a Clinical Professor of Medicine that specializes in the field of cardio-vascular imaging, pulmonary hypertension, advanced heart failure and transplantation. Dr. Haddad has over 18 years of practice in the field of cardiology. He directs Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory dedicated to translational studies in cardiovascular medicine. The laboratory focuses on (1) identifying early biomarkers of heart failure and aging, (2) bioengineering approaches to cardiovascular disease modeling and (3) novel informatic approach for the detection and risk stratification of disease. He is involved is several precision medicine initiatives in health including the Project Baseline, the Integrated Personalized Omics Profiling Initiative, the Athletic screening program at Stanford and the Strong-D cardiac rehabilitation initiative in individuals with diabetes mellitus.
-
Christiane Haeffele
Clinical Associate Professor, Medicine - Cardiovascular Medicine
Clinical Assistant Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
William Haskell
Professor (Research) of Medicine, Emeritus
Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.
-
Paul Heidenreich, MD
Professor of Medicine (Cardiovascular)
Current Research and Scholarly InterestsMy research interests include
1) The cost-effectiveness of new cardiovascular technologies.
Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.
2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.
3) Outcomes research using existing clinical and administrative datasets.
4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction). -
Mark Hlatky, MD
Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.
-
Benjamin Davies Horne
Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine
BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.
-
Stephanie Hsiao, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Stephanie Hsiao is a clinical assistant professor at Stanford Medicine and a full-time advanced heart failure/transplant cardiologist at the Palo Alto VA. She is the associate program director of the Stanford Cardiology Fellowship and the site director of Palo Alto VA. She grew up in Taipei, Taiwan. She attended undergraduate at UC Berkeley and obtained her Master’s degree in Pharmacology at Cambridge University in the UK. She obtained her M.D. from UC San Francisco. She completed her Internal Medicine residency and General Cardiology fellowship at the California Pacific Medical Center in San Francisco, where she served as the chief resident and chief cardiology fellow. She completed her advanced heart failure/transplant cardiology fellowship at Stanford in June 2022 and joined the Stanford Faculty soon after. She has a strong interest in medical education and quality improvement. Her clinical interests include HF outreach in the VA health care systems, cardiology fellowship curriculum design/development and humanism in medicine. Her research interests include multi-organ transplantations, advanced HF therapies for the underserved and CardioPalliative integration. She plans to lead a career in medical education and quality improvement to deliver exceptional and equitable care for patients needing advanced HF therapies.
-
Hirotaka Ieki
Postdoctoral Scholar, Cardiovascular Medicine
BioCardiologist in Japan.
Research interest: precision medicine in cardiovascular disease. Genomics, Exposomics. -
Gentaro Ikeda
Instructor, Medicine - Cardiovascular Medicine
BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.
-
Fumiaki Ikeno
Program Director (U.S) Japan Biodesign, Stanford Biodesign, Medicine - Med/Cardiovascular Medicine
BioProgram Director (U.S) Japan Biodesign, Stanford Biodesign
Researcher Cardiovascular Medicine, Stanford University
Faculty of Japan Reach, CARE (Center for Asian Health Research and Education) , Stanford University
Co-Director of Asia, SPARK Global, Stanford SPARK , Stanford University
Dr. Ikeno is a Researcher, Cardiovascular Medicine, Stanford University. In this role, he is responsible for pre clinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases. Currently, he is devoting himself to the international regulatory project between Japan and the United States, also known as "Harmonization by Doing", whose focus is to collaborate with regulatory agencies such as FDA, PMDA/MHLW, academia and industries for improving the regulatory process in the 2 largest medtech markets. Dr. Ikeno also devoted himself to found Japan biodesign program which is a collaborative program with University of Tokyo, Osaka University, Tohoku University, Japan Federation Medical Device Association, Ministry of Education Japan and Stanford biodesign program. Currently, Dr. Ikeno serves as the Program Director (US) for Japan Biodesign. Dr. Ikeno is co-founder and board member of US-Japan MedTech Frontier which is a non-profit cooperate to make a trans-pacific eco-system of medical device between Japan and USA.
After 9 years clinical practice as an interventional cardiologist and Family Doctor in rural areas of Japan, Dr. Ikeno came to Stanford as a Researcher and completed his Biodesign Certificate Program. Being part of the ecosystem in Silicon Valley, Dr. Ikeno participated in more than 200 medtech projects and 50 GLP studies as well as in the analysis of clinical trials for cardiovascular medicine (BARI2D, FAME, ReOPEN etc). His other academic consortium projects include Peripheral Academic Research Consortium, Global Consensus Working Group of Optical Coherence Tomography, and Japan-US consensus document for the treatment of critical limb ischemia.
Over the last decade, Dr. Ikeno has served as an advisor for medical device industries and currently serves as a chief medical officer of an incubation fund specific for medtech (Medventure Partners, Inc, Tokyo) as a spin-off from Innovation Network Corporation of Japan (INCJ) that is the largest government and private partnership fund in Japan. He is also serving as a chair of cardiovascular working group of APAN (Asian Pacific Advanced Network) that contributes the remote education, research activities, and tele-health using a specialized internet network. Dr.Ikeno is also serving as consulting faculty/lecturer roles in several universities in Japan including University of Tokyo, Osaka University, Tsukuba University etc. Dr. Ikeno has authored over 70 peer reviewed publications and textbooks and has been invited to lecture at international medical conferences. Dr. Ikeno is a council member of U.S.- Japan Council which is a non-profit organization by Japanese American. He is serving as a mentor for START-X MED which is an accelerating program for Stanford related entrepreneurs in medical fields.
Contact Information
Falk CVRC CV007
300 Pasteur Drive
Palo Alto, CA 94305-5406
